Prevalence of hot flashes in women of 40 to 65 years of age with metabolic syndrome

Imagem de Miniatura
Arquivos
art_SAU_Prevalence_of_hot_flashes_in_women_of_40_2020.PDF (125.74 KB)
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2020
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ASSOC MEDICA BRASILEIRA
Autores
SAU, Helena Proni Fonseca
CARDOSO, Maria Regina Alves
ALDRIGHI, Jose Mendes
Citação
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, v.66, n.12, p.1628-1632, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
OBJECTIVE: Hot flashes have a negative impact on the quality of life of women during the menopausal transition and thereafter. The progressive reduction in gonadal estrogen levels associated with aging promotes an accumulation of abdominal fat, dyslipidemia, and arterial hypertension, all of which are components of metabolic syndrome (MetS). The objective of the present study was to estimate the prevalence of hot flashes and evaluate their relationship with MetS in women >= 40 years of age. METHODS: This was a cross-sectional study involving women aged between 40 and 65 years. We used the Kupperman index to quantify the climacteric symptoms and the National Cholesterol Education Program Adult Treatment Panel III criteria for the diagnosis of MetS. RESULTS: 1,435 women were initially selected, and we obtained information from 647. The mean age at menopause was 45.99 years (SD 6.61 years) and the prevalence of hot flashes and MetS were 55.83% (95% CI: 52.35-59.25%) and 46.29% (95% CI: 44.75-52.53%), respectively. We identified a positive association between MetS and hot flashes (OR 1.16; 95% CI: 1.01-1.33). CONCLUSIONS: In women >= 40 years of age, hot flashes are highly prevalent and appear to be associated with MetS.
Palavras-chave
Climacteric, Perimenopause, Hot flashes, Metabolic syndrome
URI
https://observatorio.fm.usp.br/handle/OPI/39180
Referências
  1. Alva ML, 2015, DIABETIC MED, V32, P459, DOI 10.1111/dme.12647
  2. Associacao Brasileira para o Estudo da Obesidade e da Sindrome Metabolica, 2016, DIR BRAS OB 2016
  3. Schmitt ACB, 2013, MENOPAUSE, V20, P470, DOI 10.1097/gme.0b013e318272c938
  4. Charkoudian N, 2017, CLIN AUTON RES, V27, P149, DOI 10.1007/s10286-017-0420-z
  5. Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
  6. Da Fonseca AM, 2013, GYNECOL ENDOCRINOL, V29, P116, DOI 10.3109/09513590.2012.730570
  7. Sorpreso ICE, 2015, REV ASSOC MED BRAS, V61, P553, DOI 10.1590/1806-9282.61.06.553
  8. Freedman RR, 2014, J STEROID BIOCHEM, V142, P115, DOI 10.1016/j.jsbmb.2013.08.010
  9. Gartoulla P, 2015, MENOPAUSE, V22, P694, DOI 10.1097/GME.0000000000000383
  10. Gordon JL, 2016, MENOPAUSE, V23, P1189, DOI 10.1097/GME.0000000000000689
  11. Harlow SD, 2012, J CLIN ENDOCR METAB, V97, P1159, DOI 10.1210/jc.2011-3362
  12. IWASE S, 1991, J GERONTOL, V46, pM1, DOI 10.1093/geronj/46.1.M1
  13. Jackson EA, 2016, J WOMENS HEALTH, V25, P1204, DOI 10.1089/jwh.2015.5670
  14. Kozakowski J, 2017, MENOPAUSE REV, V16, P61, DOI 10.5114/pm.2017.68594
  15. Lambert E, 2013, AM J HYPERTENS, V26, P250, DOI 10.1093/ajh/hps016
  16. Lee SW, 2012, ARCH GYNECOL OBSTET, V285, P541, DOI 10.1007/s00404-011-2016-5
  17. Mancini MC, 2004, TRATADO OBESIDADE
  18. Mishra GD, 2012, MENOPAUSE, V19, P549, DOI 10.1097/gme.0b013e3182358d7c
  19. Pinkerton JV, 2016, MENOPAUSE, V23, P1060, DOI 10.1097/GME.0000000000000678
  20. Ryu KJ, 2015, MENOPAUSE, V22, P1239, DOI 10.1097/GME.0000000000000461
  21. Saccomani S, 2017, MENOPAUSE, V24, P1065, DOI 10.1097/GME.0000000000000884
  22. Sarrel P, 2015, MENOPAUSE, V22, P260, DOI [10.1097/GME.0000000000000320, 10.1097/gme.0000000000000320]
  23. SILVA NL, 1986, AM J PHYSIOL, V250, pR625
  24. Thurston RC, 2008, CIRCULATION, V118, P1234, DOI 10.1161/CIRCULATIONAHA.108.776823
  25. Tuomikoski P, 2017, MATURITAS, V97, P61, DOI 10.1016/j.maturitas.2016.12.010

Coleções
Artigos e Materiais de Revistas Científicas - FM/MFT